High mobility group box 1 inhibition by BoxA attenuates ovalbumin-induced allergic rhinitis in mice. (17th February 2022)

• Record Type: Journal Article
• Authors: Yue, Liyan; Dong, Jinhui; Wang, Jianxing; Yin, Xiaoyan; Ren, Xiumin; Xu, Ou; Shan, Chunguang
• Is Part Of: Autoimmunity. Volume 55:Number 2(2022)
• Page Start: 118
• Page End: 126
• Publication Date: 2022-02-17
• Subjects: HMGB1 -- allergic rhinitis -- BoxA -- inhibition -- ovalbumin -- mice; Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; 571.973
• DOI: 10.1080/08916934.2021.2021512
• Languages: English
• ISSNs: 0891-6934

Abstract

Abstract: This study was designed to evaluate the effects of BoxA on allergic rhinitis (AR). Ovalbumin (OVA)-induced AR mice model was employed and BoxA was administered to AR mice. AR symptoms, levels of cytokines and chemokines, and the expression of high mobility group box 1 (HMGB1), TLR2, and TLR4 were measured. BoxA treatment significantly ameliorated AR symptoms, decreased level of histamine, OVA-specific antibodies, suppressed the infiltration of immune cells in nasal tissues, inhibited the expression of IL-4, IL-6, IL-5, TNF-α, IL-13, IL-17, IL-2 while promoting the expression of IL-10, suppressed the expression of HMGB1, TLR2, and TLR4 in AR mice. BoxA ameliorated allergic rhinitis in mice by inhibiting HMGB1.